Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 46 h ago

EyePoint, Inc.: Cormorant Asset Management, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Cormorant Asset Management amended its Schedule 13G filing on EyePoint, Inc., updating its beneficial ownership stake with the SEC under accession number 0001172661-26-005296. The filing reflects a change in the investment firm's reported position in the clinical-stage eye disease drug developer. The exact size and direction of the stake change were not specified in the filing headline. Investors watch 13G amendments for signals about institutional conviction in small-cap biotech names like EyePoint.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Cormorant Asset Management, LP, EyePoint, Inc.